These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26796222)

  • 1. Optimal control with multiple human papillomavirus vaccines.
    Malik T; Imran M; Jayaraman R
    J Theor Biol; 2016 Mar; 393():179-93. PubMed ID: 26796222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
    Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
    Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections.
    Garbuglia AR; Gentile M; Del Nonno F; Lorenzini P; Lapa D; Lupi F; Pinnetti C; Baiocchini A; Libertone R; Cicalini S; Capobianchi MR; Ammassari A
    J Clin Virol; 2015 Nov; 72():49-54. PubMed ID: 26397204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global stability of equilibria in a two-sex HPV vaccination model.
    Elbasha EH
    Bull Math Biol; 2008 Apr; 70(3):894-909. PubMed ID: 17999117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.
    Stanley M; Joura E; Yen GP; Kothari S; Luxembourg A; Saah A; Walia A; Perez G; Khoury H; Badgley D; Brown DR
    Vaccine; 2021 Apr; 39(16):2214-2223. PubMed ID: 33658126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential impact of introducing a nonavalent HPV vaccination.
    Bogani G; Taverna F; Lombardo C; Signorelli M; Chiappa V; Casarin J; Scaffa C; Leone Roberti Maggiore U; Recalcati D; Ditto A; Martinelli F; Borghi C; Perotto S; Ferrero S; Lorusso D; Raspagliesi F
    Int J Gynaecol Obstet; 2018 Sep; 142(3):338-342. PubMed ID: 29858884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg.
    Latsuzbaia A; Arbyn M; Tapp J; Fischer M; Weyers S; Pesch P; Mossong J
    Cancer Epidemiol; 2019 Dec; 63():101593. PubMed ID: 31499377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
    Chesson HW; Laprise JF; Brisson M; Markowitz LE
    J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deterministic modelling for transmission of Human Papillomavirus 6/11: impact of vaccination.
    Ribassin-Majed L; Lounes R; Clemençon S
    Math Med Biol; 2014 Jun; 31(2):125-49. PubMed ID: 23475425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of risk-structured vaccination model for the dynamics of oncogenic and warts-causing HPV types.
    Alsaleh AA; Gumel AB
    Bull Math Biol; 2014 Jul; 76(7):1670-726. PubMed ID: 25033777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.
    Chatterjee A
    Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
    Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
    J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-licensure monitoring of HPV vaccine in the United States.
    Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
    Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.